Skip to content
Catalyst
Search

Endpoint

Hamilton Depression Rating Scale (HDRS) total score

CAT:outcome/hdrs-total-scorereported in points5 findings from 5 compounds

Open in the graph: Hamilton Depression Rating Scale (HDRS) total score

What moved it

How to read these marks

5 findings · 5 compounds · 2 null · by evidence strength

CompoundDirectionFindingsStrongest evidence
paroxetinedown1Evidence strength: moderate.
resveratrolno effect1Evidence strength: moderate.
curcumindown1Evidence strength: very limited.
magnesium(2+)down1Evidence strength: very limited.
methylphenidateno effect1Evidence strength: very limited.

Reported to move it

3 findings

  • paroxetine — decreases

    Evidence strength: moderate.Finding
    “The HAMD score showed significant decrease in the paroxetine treatment group compared to control group (SMD -2.14, 95% CI -2.73 to -1.56, P <.00001).”
    Quoted verbatim from The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson's disease: A meta-analysis..
    Study
    meta-analysis
    Dose
    20 mg/d in most trials
    Population
    Patients with depression and idiopathic Parkinson's disease; paroxetine added to background anti-parkinsonian drug therapy versus that therapy alone (or placebo in 3 trials); 25 trials, 2126 patients

    Effect -2.14 standardised mean difference, 95% CI -2.73 to -1.56

    The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson's disease: A meta-analysis.2023PMID:3765379510.1097/MD.0000000000034687Permalink

  • magnesium(2+) — decreases

    Evidence strength: very limited.Finding
    “The reduction in HDRS total score was greater in the intervention group than in the control group (-6.35 vs -2.80, p < 0.001), particularly in the domains of mood and insomnia.”
    Quoted verbatim from Magnesium supplementation as an adjunct to fluoxetine therapy for depression..
    Study
    RCT
    Duration
    6 weeks
    Dose
    magnesium 250 mg/day oral, adjunct to fluoxetine 20 mg/day
    Population
    adults aged 18-45 with new-onset or chronic depression, all receiving background fluoxetine 20 mg/day

    Magnesium supplementation as an adjunct to fluoxetine therapy for depression.2026PMID:4191693710.12809/eaap25122Permalink

  • curcumin — decreases

    Evidence strength: very limited.Finding
    “Chronic supplementation with curcumin produced significant antidepressant behavioral response in depressed patients by reduction of 17-item Hamilton Depression Rating Scale and Montgomery-Asberg Depression Rating Scale scores.”
    Quoted verbatim from Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study..
    Study
    RCT
    Duration
    6 weeks
    Dose
    1000 mg/day (2 capsules)
    Population
    adult men (31-59 years) with major depressive disorder, continuing their existing antidepressant medication regimen in both curcumin and placebo arms (adjunctive therapy)

    Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.2015PMID:2606633510.1097/JCP.0000000000000352Permalink

Measured, no effect detected

2 findings

  • resveratrol — no detected effect on

    Evidence strength: moderate.FindingNull result
    “HDRS scores and its changes, ESRS score, and frequency of other complications were not significantly different between resveratrol and placebo groups.”
    Quoted verbatim from Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial..
    Study
    RCT
    Duration
    8 weeks
    Dose
    200 mg/d
    Population
    Patients with stable schizophrenia on a stable dose of risperidone in both arms; resveratrol versus matched placebo

    Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.2020PMID:3337267910.1093/ijnp/pyaa006Permalink

  • methylphenidate — no detected effect on

    Evidence strength: very limited.FindingNull result
    “There is no clear evidence of an effect on anxiety (MD -0.20, 95% CI -4.84 to 4.44; 1 trial, 19 participants; change scores; Hamilton Anxiety Scale (HAM-A; scored from 0 to 56); very low-certainty evidence) or depression (MD 2.80, 95% CI -0.09 to 5.69; 1 trial, 19 participants; change scores; Hamilton Depression Scale (HAM-D; scored from 0 to 52); very low-certainty evidence) in analyses comparing IR methylphenidate with placebo.”
    Quoted verbatim from Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults..
    Study
    RCT
    Participants
    19
    Population
    adults with ADHD, immediate-release methylphenidate versus placebo; secondary outcome (depression)

    Effect 2.8 mean difference, 95% CI -0.09 to 5.69

    Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.2021PMID:3346004810.1002/14651858.CD013011.pub2Permalink

How it is measured

Total score on the clinician-administered Hamilton Depression Rating Scale (HDRS / HAM-D), summed across its items into a single continuous depression-severity score.

Sources cited

5 papers

Subject
hamilton depression rating scale (hdrs) total score
Findings
5
Papers
5